Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) is a clinical-stage biotechnology company focused on discovering, developing and delivering potentially curative therapies that address the underlying drivers of heart disease. The Tenaya Therapeutics news feed highlights company announcements, clinical data updates and financial disclosures related to its gene therapy and small molecule programs for genetic cardiomyopathies and heart failure.
News about Tenaya frequently centers on TN-201, its AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), and TN-401, its AAV9-based gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Company press releases provide interim safety, biopsy and early efficacy results from the MyPEAK-1 and RIDGE-1 Phase 1b/2 clinical trials, including observations on protein expression, arrhythmia measures and biomarkers.
Investors and followers of TNYA can also find updates on regulatory interactions, such as FDA designations and clinical hold communications, as well as information on Tenaya’s capital-raising activities through public offerings described in SEC filings and related press releases. Additional news items cover participation in scientific and investor conferences, late-breaking presentations at major cardiology and gene therapy meetings, and publications that describe Tenaya’s research platforms and preclinical findings.
This page aggregates these disclosures so readers can review Tenaya Therapeutics’ latest reported milestones, from clinical trial progress for TN-201 and TN-401 to developments in its broader pipeline, including the TN-301 small molecule HDAC6 inhibitor and early-stage preclinical programs. For those tracking TNYA, the news stream offers a consolidated view of how the company reports advancing its mission to address genetic drivers of heart disease.
Tenaya Therapeutics (NASDAQ: TNYA) presented interim MyPEAK-1 Phase 1b/2a data for TN-201 on Nov 8, 2025. Single-dose TN-201 at 3E13 vg/kg and 6E13 vg/kg was generally well tolerated with no dose-limiting toxicities and manageable immunosuppression.
Key efficacy signals: average MyBP-C protein +4% in Cohort 1 at Week 52, early +14% MyBP-C in a Cohort 2 patient at Week 12, LVPWT reductions 21%–39%, LVMI reductions 12%–22% in two Cohort 1 patients, and Cardiac Troponin I declines 48%–74%. Two treatment-related serious AEs were reported; reversible liver enzyme elevations were the most common AE.
Tenaya Therapeutics (NASDAQ: TNYA) announced two late-breaking oral presentations at the American Heart Association Scientific Sessions 2025 on November 8–9, 2025 highlighting new clinical and preclinical data.
Key items: interim safety and efficacy results from dose cohorts 1 and 2 of the MyPEAK-1 Phase 1b/2a study of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy will be presented on Nov 8, 2025, 10:25–10:35 am CT by Milind Y Desai, M.D., MBA. A separate late-breaking oral presentation of a cellular reprogramming gene therapy showing significant and durable improvement in cardiac function in a pig ischemic heart failure model will be presented on Nov 9, 2025, 8:00–8:10 am CT by Kathy Ivey.
Tenaya will host a webcast and conference call on Nov 10, 2025 at 8:00 am ET to discuss MyPEAK-1 data; presentations will be posted on the company website after each session.
Tenaya Therapeutics (NASDAQ: TNYA) announced that CEO Faraz Ali will participate in a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on October 14, 2025. Company management will hold virtual 1x1 meetings on October 15, 2025. The fireside chat will be webcast and accessible from the Investors section of Tenaya's website, with an archived replay available for approximately 30 days after the conference.
Tenaya Therapeutics (NASDAQ: TNYA) announced CEO Faraz Ali will participate in investor and industry conferences in October 2025. Key events: Cell & Gene Meeting on the Mesa on October 6 with a panel at 8:00–9:00 AM MT and a company presentation at 12:00–12:15 PM MT; and the Chardan Annual Genetic Medicines Conference on October 21 with a panel 12:00–12:40 PM ET titled "In Vivo Gene Therapies for Genetic Cardiac Diseases."
The Chardan panel will be webcast live and an archived replay will be available on Tenaya's investor website for ~30 days.
Tenaya Therapeutics (NASDAQ: TNYA), a clinical-stage biotech company focused on heart disease treatments, has granted stock options to two new non-executive employees. The grants include options to purchase 202,000 shares of common stock at an exercise price of $1.20 per share, matching the closing price on September 15, 2025.
The options have a ten-year term with a four-year vesting schedule: 25% vests after one year, followed by monthly vesting of 1/48th of shares. These grants were made under the company's 2024 Inducement Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Tenaya Therapeutics (NASDAQ: TNYA), a clinical-stage biotech company focused on developing curative therapies for heart disease, announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference.
CEO Faraz Ali will engage in a fireside chat on September 9, 2025, at 4:50 pm ET. Investors can access the live webcast through Tenaya's website's Investor section, with a replay available for approximately 30 days after the event.
Tenaya Therapeutics (NASDAQ: TNYA) presented interim data from MyClimb™, the largest natural history study of pediatric patients with MYBPC3-associated hypertrophic cardiomyopathy (HCM), at the European Society of Cardiology Congress 2025. The study analyzed 213 participants from 27 centers across multiple countries.
Key findings revealed that 93% of participants had nonobstructive HCM, which currently lacks approved treatments. The study identified three genetic inheritance patterns with distinct risk profiles: Homozygous patients typically died or needed heart transplant before age one, Compound Heterozygous patients showed severe symptoms with 27% requiring transplant or dying, and Heterozygous patients had later onset but still significant complications.
Importantly, Left Ventricular Mass Index (LVMI) emerged as a significant predictor of risk, with every 10-unit increase associated with a 10% higher hazard of serious events, potentially serving as a surrogate marker for future gene therapy studies.
Tenaya Therapeutics (NASDAQ: TNYA), a clinical-stage biotech company focused on developing curative therapies for heart disease, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's CEO, Faraz Ali, will engage in a fireside chat on Tuesday, August 12, 2025 at 11:30 am ET.
Investors can access the live webcast through Tenaya's website's Investor section, with a replay available for approximately 30 days after the event.
Tenaya Therapeutics (NASDAQ: TNYA) reported significant progress in its Q2 2025 clinical trials for genetic cardiomyopathies. The company completed enrollment in Cohorts 1 and 2 of the MyPEAK-1 trial for TN-201 (MYBPC3-associated HCM) and received positive DSMB safety reviews enabling expansion cohorts. For TN-401 (PKP2-associated ARVC), Cohort 1 enrollment is complete and the first patient in Cohort 2 has been dosed following DSMB recommendation.
Key financial metrics include $71.7 million in cash and equivalents, with runway extending into H2 2026. Q2 2025 showed a net loss of $23.3 million ($0.14 per share), improved from $29.4 million loss in Q2 2024. The company expects important data readouts for both TN-201 and TN-401 in Q4 2025.
Tenaya Therapeutics (NASDAQ: TNYA) announced positive safety reviews from independent Data Safety Monitoring Boards (DSMBs) for its two cardiovascular gene therapy clinical trials. The MyPEAK-1 trial for TN-201 treating MYBPC3-associated hypertrophic cardiomyopathy has completed enrollment in both dose cohorts, with follow-up data expected in Q4 2025. Early results showed robust RNA expression and improved heart failure symptoms in Cohort 1 patients.
The RIDGE-1 trial for TN-401, targeting PKP2-associated arrhythmogenic right ventricular cardiomyopathy, has dosed its first patient in Cohort 2 at 6E13 vg/kg. Initial Cohort 1 data is expected in Q4 2025. Both trials received endorsements to proceed with expansion cohorts, highlighting favorable safety profiles.